|Description||GIBH-130 is an effective inhibitor of neuroinflammation. GIBH-130 significantly suppresses theIL-1βsecretion by activated microglia (IC50=3.4 nM). GIBH-13 constitutes a unique chemical probe for pathogenesis research and drug development of AD, and it also suggests microglia-based phenotypic screenings that target neuroinflammation as an effective and feasible strategy to identify novel anti-AD agents.|
|Synonyms||(4-methyl-6-phenylpyridazin-3-yl)-(4-pyrimidin-2; -ylpiperazin-1-yl)methanone; (4-methyl-6-phenylpyridazin-3-yl)(4-(pyrimidin-2-yl)piperazin-1-yl)methanone; GIBH-130; GIBH130; GIBH 130|
|Solubility||10 mM in DMSO|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
|Boiling Point||664.5±65.0 ℃ at 760 Torr|
Reslizumab is a humanized monoclonal antibody resistant to interleukin-5 (IL-5). It is approved for additional maintenance treatment of patients with severe ast...
Secukinumab is a recombinant human IgG1κ monoclonal antibody that specifically binds to and inhibits interleukin (IL)-17A. Secukinumab was developed by Novartis...
IL5 receptor antagonist
guselkumab is a selectively blocking agent for interleukin-23 (IL-23), a cytokine involved in plaque psoriasis. guselkumab was approved by FDA as an anti-inflam...
Ustekinumab is a human monoclonal antibody approved for the treatment of psoriasis and Crohn's disease. Ustekinumab acts via blocking IL-12 and IL-23.
Pentagalloylglucose, a polyphenol isolated from the fruits of Pistacia lentiscus, increases a population of Treg cells in conjunction with Treg-inducing factors...
Ginsenoside Rg5, a main constituent isolated from red ginseng, exhibits anti-inflammatory property as in LPS-stimulated alveolar macrophages it inhibited the ex...
CK-119, a dihydropyridazino-pyridazine compound, is a potent IL-1 blocker to inhibit cell growth of fibroblast-like corneal and conjunctival cells mainly throug...